Bond.az White LogoBond.az Black Logo

Barclays Starts CMC with Equalweight

Barclays initiated coverage on Commercial Metals Company (CMC) with an Equalweight rating and $75 target. Stock at $70.70. Q2 results mixed.

Jack Scott
ByJack Scott- Senior Editor
|
0

Barclays initiated coverage on Commercial Metals Company (NYSE:CMC) with an Equalweight rating and a price target of $75.00. The stock trades at $70.70.

Analyst Richard Garchitorena said shares are fairly valued given the company's position in the construction cycle. The debt-to-equity ratio stands at 0.82.

Barclays views recent acquisitions as positive, expanding exposure to construction solutions and margins.

In other news, CMC reported mixed Q2 fiscal 2026 results. Revenue of $2.13B beat expectations, but EPS of $1.16 missed the $1.30 forecast.

More News
Today / 08:35
|
482

Barclays starts Agnico-Eagle at Overweight

Barclays initiates Agnico-Eagle Mines with Overweight rating and $213 price target. Low-cost gold miner with strong financial health.

0
Today / 08:14
|
343

UBS Upgrades Alcoa Stock Rating

UBS upgrades Alcoa stock rating to Buy, raises price target to $80, citing aluminum supply constraints and positive outlook.

0
Today / 08:13
|
233

JPMorgan Raises Spotify Target to $650 on AI Deal

JPMorgan raised Spotify's target to $650 after AI deal and 2030 goals. Strong margin targets and growth prospects highlighted.

0
Today / 07:01
|
523

Goldman Sachs Reinstates Ageas with Neutral

Goldman Sachs reinstates Ageas with Neutral rating, price target EUR70.

0
Yesterday / 21:33
|
306

Bernstein Starts Incyte with Growth Concerns

Bernstein starts Incyte coverage with Market Perform rating and $99 target, highlighting Jakafi patent loss and growth concerns.

0
Yesterday / 21:32
|
759

Bernstein Initiates BioNTech Coverage with Concerns

Bernstein initiates BioNTech coverage with Market Perform rating and $96 target, citing pipeline concerns.

0
Yesterday / 21:31
|
915

Bernstein Starts Revolution Med at Market Perform

Bernstein initiates Revolution Medicines coverage with Market Perform rating and $151 target. Stock trades at $153.73.

0
Yesterday / 21:30
|
792

Bernstein Initiates Neurocrine with Outperform Rating

Bernstein initiates Neurocrine Biosciences with an outperform rating and $221 price target. Highlights Crenessity's potential and stock upside.

0
Yesterday / 20:02
|
615

TD Cowen Cuts Orthofix Medical Target to $12

TD Cowen cuts Orthofix Medical price target to $12 on CMS rate cuts. Stock near 52-week low. Hold rating maintained.

0
Yesterday / 18:52
|
535

BofA Raises Nio Price Target to $6.80

BofA raises Nio price target to $6.80 on improved margin outlook. Get the latest analysis and stock insights at Bond.az.

0
Yesterday / 18:02
|
442

Chemours, Solstice Stock Drops: Buying Opportunity

BMO Capital Markets sees recent declines in Chemours and Solstice stocks as buying opportunities after EPA extends refrigerant transition deadline.

0
Yesterday / 17:51
|
885

BTIG cuts Lightspeed price target to $12

BTIG cut Lightspeed POS price target to $12 from $15, maintaining Buy. Stock at $8.38. Company guides 12-16% organic gross profit growth for FY2027.

0
...